Seawolf launches with $100M to advance non-viral gene therapies

  • <<
  • >>

San Diego-based Seawolf Therapeutics has emerged from stealth, having raised $100 million to advance a portfolio of therapeutics that leverage its redosable lipid nanoparticle-based DNA delivery system.

Founding investor Versant Ventures led the seed round, followed by the Series A financing with Versant, MPM BioImpact, and Novartis Venture Fund, and participation from Eli Lilly and Company, CRISPR Therapeutics AG, Sixty Degree Capital, Alexandria Venture Investments, Pathway to Cures (the philanthropic venture arm of the National Bleeding Disorders Foundation), and others.

Seawolf says its TRIDENT DNA delivery system matches the potency, redosability, safety and scalability of RNA-based LNP therapies but overcomes their short-lived expression by delivering DNA-based payloads. To do so, the TRIDENT system consists of a proprietary LNP carrying an immune quiet DNA that encodes a therapeutic transgene and an auxiliary factor that facilitates nuclear access.

Seawolf also announced a multi-target research collaboration and exclusive license agreement with Sanofi to develop undisclosed therapies for bleeding disorders and additional unnamed indications for up to $1.2 billion in research, development amd commercial milestones, as well as tiered royalties on sales of any products resulting from the collaboration.

Subscribe to our e-Newsletters
Stay up to date with news, articles and insights relevant to cell and gene therapy development and manufacturing. Plus, get special offers from Cell & Gene Therapy Review delivered right to your inbox! Sign up now!

More news